Anyara fails in renal cell cancer but 'potential biomarker' identified
This article was originally published in Scrip
Executive Summary
Initial data from Active Biotech's Phase II/III study of its immunotherapy Anyara for the treatment of renal cell cancer (RCC) show that it failed to meet the primary endpoint of overall survival (OS).